Alexander Hardy's Insider Trades & SAST Disclosures
Alexander Hardy's most recent trade in Biomarin Pharmaceutical Inc. - Registered Shares was a trade of 61,750 Stock Option (Right to Buy Common Stock) done . Disclosure was reported to the exchange on March 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Alexander Hardy.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biomarin Pharmaceutical In... | Alexander Hardy | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 61,750 | 61,750 | - | - | Stock Option (Right to Buy Common Stock) | |
| Biomarin Pharmaceutical In... | Alexander Hardy | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 44,360 | 175,583 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Alexander Hardy | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.44 per share. | 14 Mar 2025 | 2,933 | 131,223 (0%) | 0% | 69.4 | 203,668 | Common Stock |
| Biomarin Pharmaceutical In... | Hardy Alexander | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 66.03 per share. | 29 Nov 2024 | 14,295 | 134,156 (0%) | 0% | 66.0 | 943,899 | Common Stock |
| Biomarin Pharmaceutical In... | Hardy Alexander | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 56.01 per share. | 29 Nov 2024 | 300 | 148,451 (0%) | 0% | 56.0 | 16,802 | Common Stock |
| Biomarin Pharmaceutical In... | Alexander Hardy | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 44,050 | 44,050 | - | - | Stock Option (Right to Buy Common Stock) | |
| Biomarin Pharmaceutical In... | Alexander Hardy | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 32,780 | 148,151 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Hardy Alexander | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 150,529 | 150,529 | - | - | Stock Option (Right to Buy Common Stock) | |
| Biomarin Pharmaceutical In... | Alexander Hardy | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 68,039 | 68,039 (0%) | 0% | 0 | Common Stock | |
| Biomarin Pharmaceutical In... | Hardy Alexander | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Dec 2023 | 47,332 | 115,371 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges